David A. Siegel Humacyte, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Humacyte, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 243,100 shares of HUMA stock, worth $286,858. This represents 0.0% of its overall portfolio holdings.
Number of Shares
243,100
Previous 367,100
33.78%
Holding current value
$286,858
Previous $767,000
44.98%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding HUMA
# of Institutions
156Shares Held
43.2MCall Options Held
383KPut Options Held
490K-
Vanguard Group Inc Valley Forge, PA7.52MShares$8.87 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.14MShares$8.43 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.1MShares$3.65 Million0.0% of portfolio
-
State Street Corp Boston, MA2.41MShares$2.84 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.1MShares$2.47 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $122M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...